We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

X-82 to Treat Age-related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02348359
Recruitment Status : Terminated (Interim analysis found study had achieved primary objective)
First Posted : January 28, 2015
Results First Posted : June 27, 2018
Last Update Posted : February 11, 2022
Sponsor:
Collaborators:
SynteractHCR
International Drug Development Institute
Information provided by (Responsible Party):
Tyrogenex

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.

Condition or disease Intervention/treatment Phase
Age-Related Macular Degeneration (AMD) Macular Degeneration Exudative Age-related Macular Degeneration AMD Macular Degeneration, Age-related, 10 Eye Diseases Retinal Degeneration Retinal Diseases Drug: X-82 Drug: Anti-VEGF Drug: Placebo Phase 2

Detailed Description:

Subjects will be randomized in a 1:1:1:1 ratio to the following dose groups:

  • X-82 50 mg plus ivt anti-VEGF prn
  • X-82 100 mg plus ivt anti-VEGF prn
  • X-82 200 mg plus ivt anti-VEGF prn
  • Placebo plus ivt anti-VEGF prn

Subjects will be treated for a total of 52 weeks with one of three doses of X-82 or placebo.

Primary Efficacy Outcome:

The primary efficacy outcome is the change in visual acuity score from Day -1 to 52 Weeks after randomization.

Safety Outcomes:

Systemic and ocular safety will be evaluate by assessing ECG, laboratory analyses, adverse events and serious adverse events.

Approximately 132 subjects will be randomized into one of the four arms (33 subjects per dose group).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 157 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD
Actual Study Start Date : March 16, 2015
Actual Primary Completion Date : December 12, 2017
Actual Study Completion Date : January 12, 2018

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: 50 mg of X-82 plus ivt anti-VEGF prn
Subject will administer one 50 mg tablet of X-82 and one placebo tablet once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
 Drug: X-82
Other Name: X-82 tablets

Drug: Anti-VEGF
Other Names:
  • Aflibercept (Eylea)
  • Ranibizumab (Lucentis)
  • Bevacizumab (Avastin)
Experimental: 100 mg of X-82 plus ivt anti-VEGF prn
Subject will administer two 50 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
 Drug: X-82
Other Name: X-82 tablets

Drug: Anti-VEGF
Other Names:
  • Aflibercept (Eylea)
  • Ranibizumab (Lucentis)
  • Bevacizumab (Avastin)
Experimental: 200 mg of X-82 plus ivt anti-VEGF prn
Subject will administer two 100 mg tablets of X-82 once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
 Drug: X-82
Other Name: X-82 tablets

Drug: Anti-VEGF
Other Names:
  • Aflibercept (Eylea)
  • Ranibizumab (Lucentis)
  • Bevacizumab (Avastin)
Placebo Comparator: Placebo plus ivt anti-VEGF prn
Subject will administer two placebo tablets once daily. Subjects will be assessed for the need for retreatment with ivt anti-VEGF therapy at each visit.
 Drug: Anti-VEGF
Other Names:
  • Aflibercept (Eylea)
  • Ranibizumab (Lucentis)
  • Bevacizumab (Avastin)

Drug: Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Mean Change in Visual Acuity Score From Day -1 to Week52 [ Time Frame: Week 52 ]
    The primary outcome is the change in the visual acuity score from Day -1 to 52 weeks after randomization.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants mush have wet AMD which has been diagnosed and treated with anti-VEGF in one or both eyes for at least 6 months prior to joining the study and has required at least two prior injections of intravitreal (ivt) anti-VEGF at intervals of not greater than 6 weeks for the past two injections in the eye that is selected to be the study eye.
  • Must have demonstrated a reduction in macular fluid or macular thickness in the study eye 14 days following an anti-VEGF injection at Screening Visit 1
  • Early Treatment Diabetic Retinopathy (ETDRS) Best Corrected Visual Acuity (BCVA) of 25 letters (20/320) or better in both eyes

Exclusion Criteria:

  • Previous vitrectomy to the study eye within 30 days of Screening Visit 1
  • Choroidal neovascularization (CNV) due to causes other than AMD
  • Proliferative diabetic retinopathy in either eye
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02348359


Locations
Layout table for location information
United States, Arizona
Tucson, Arizona, United States
United States, California
Beverly Hills, California, United States
Huntington Beach, California, United States
Redlands, California, United States
Sacramento, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
Golden, Colorado, United States
United States, Connecticut
New London, Connecticut, United States
United States, Florida
Fort Myers, Florida, United States
Lakeland, Florida, United States
Melbourne, Florida, United States
Miami, Florida, United States
Palm Beach Gardens, Florida, United States
United States, Georgia
Augusta, Georgia, United States
United States, Illinois
Lemont, Illinois, United States
Oak Forest, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Maryland
Baltimore, Maryland, United States
Glen Burnie, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Springfield, Massachusetts, United States
United States, New Hampshire
Portsmouth, New Hampshire, United States
United States, New Jersey
Bloomfield, New Jersey, United States
United States, New York
Albany, New York, United States
New York, New York, United States
United States, North Carolina
Asheville, North Carolina, United States
Charlotte, North Carolina, United States
United States, Ohio
Cleveland, Ohio, United States
Youngstown, Ohio, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
Abilene, Texas, United States
Austin, Texas, United States
Houston, Texas, United States
The Woodlands, Texas, United States
United States, Virginia
Richmond, Virginia, United States
Sponsors and Collaborators
Tyrogenex
SynteractHCR
International Drug Development Institute
Investigators
Layout table for investigator information
Principal Investigator: Daniel E Salazar, PhD Study PI
  Study Documents (Full-Text)

Documents provided by Tyrogenex:
Study Protocol  [PDF] September 12, 2017
Statistical Analysis Plan  [PDF] September 11, 2017

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Tyrogenex
ClinicalTrials.gov Identifier: NCT02348359    
Other Study ID Numbers: X82-OPH-201
First Posted: January 28, 2015    Key Record Dates
Results First Posted: June 27, 2018
Last Update Posted: February 11, 2022
Last Verified: February 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Tyrogenex:
Vascular Endothelial Growth Factor (VEGF)
Platelet Derived Growth Factor (PDGF)
AMD
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Eye Diseases
Retinal Diseases
Retinal Degeneration
Eye Diseases, Hereditary
Ranibizumab
Aflibercept
 Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors